Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21424379 | 0.86 | NPC1 (0.46) | RAB9ANPC1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16554719 | 0.81 | PTGS2 (0.53) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL5713551 | 0.77 | NPC1 (0.73) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL25347779 | 0.77 | SMO (0.56) | RAB9ANPC1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16164495 | 0.77 | PIK3CA (0.44) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL19783077 | 0.76 | NPSR1 (0.44) | — | |
| SCHEMBL24769827 | 0.75 | RAB9A (0.74) | RAB9ANPC1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL11056864 | 0.75 | NPC1 (0.58) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL19963526 | 0.75 | RAB9A (0.59) | RAB9ANPC1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16554359 | 0.74 | ALDH1A1 (0.49) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-109689649-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2022-07-19 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-10730868-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3484881-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20190300520-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730868-B2 | Bicyclic heteroaryl substituted compounds | F2, PF4, F2RL3 | RAB9A 1522/4885NPC1 2002/4885ALDH1A1 1904/4885 |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | RAB9A 667/4885NPC1 2639/4885ALDH1A1 1618/4885 |
| US-20190300520-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | PF4, F2, F2RL3 | RAB9A 1571/4885NPC1 1904/4885ALDH1A1 1537/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | RAB9A 748/4885NPC1 2194/4885ALDH1A1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.